Nuclear factor erythroid 2-related factor 2 as targets to treat chronic obstructive pulmonary disease: toward new perspectives
Therapeutic Advances in Respiratory Disease · 2026-08 · 20
DOI: 10.1177/17534666261461164 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 16.08.2026. Verfasst von Haotian Chu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases, Henan Province & Education Ministry of P. R. China, Henan University o…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, NF-E2-Related Factor 2. Die Arbeit nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, national key research and development program of china, Special Scientific Research Project for Chinese Medicine in Henan Province’s “Double First-Class” Discipline Development Plan.
Themen: COPD
Abstract (Originalsprache)
Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterized by persistent airflow limitation and driven by interconnected pathways of oxidative stress, inflammation, and cell death. While nuclear factor E2-related factor 2 (Nrf2) is well-established as a central regulator of antioxidant defense, its role in COPD is now understood to be far more extensive. Beyond redox balance, Nrf2 modulates inflammatory responses and critical processes like autophagy, apoptosis, and ferroptosis, highlighting its pleiotropic nature and therapeutic potential. This review delineates the multifaceted functions of Nrf2 in COPD and explores its promise as a target for precision therapy, providing a foundation for future research and drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases, Henan Province & Education Ministry of P. R. China, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
- Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan 450046, China.
ORCID-Profile: Xuejie Shao
Förderung
- National Natural Science Foundation of China
- national key research and development program of china
- Special Scientific Research Project for Chinese Medicine in Henan Province’s “Double First-Class” Discipline Development Plan
- Program for Scienee & Technology Innovation Talents in Universitiesand Colleges of Henan Province
Zitieren
APA
Chu, H., Shao, X., Zhao, D., Zhao, P., Lu, R., Wang, C., Tian, Y., & Zhang, L. (2026). Nuclear factor erythroid 2-related factor 2 as targets to treat chronic obstructive pulmonary disease: toward new perspectives. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261461164
Vancouver
Chu H, Shao X, Zhao D, Zhao P, Lu R, Wang C, et al. Nuclear factor erythroid 2-related factor 2 as targets to treat chronic obstructive pulmonary disease: toward new perspectives. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261461164
BibTeX
@article{Chu2026,
author = {Chu, Haotian and Shao, Xuejie and Zhao, Di and Zhao, Peng and Lu, Ruilong and Wang, Chen and Tian, Yange and Zhang, Lanxi},
title = {Nuclear factor erythroid 2-related factor 2 as targets to treat chronic obstructive pulmonary disease: toward new perspectives},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
volume = {20},
doi = {10.1177/17534666261461164}
}
EUVIMED